论文部分内容阅读
目的探讨分析他汀类降脂药物对冠心病血液流变学改变的影响。方法 60例冠心病患者,随机分为观察组和对照组,各30例。对照组给予阿托伐他汀钙片治疗,观察组给予瑞舒伐他汀治疗,比较分析两组患者治疗前后的血液流变学水平以及心功能指标。结果两组患者治疗前纤维蛋白原、血浆粘度、全血低切粘度、全血高切粘度指标比较,差异无统计学意义(P>0.05),治疗后,观察组上述指标均低于对照组,差异具有统计学意义(P<0.05)。治疗前,观察组患者左心室射血分数(LVEF)、左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)比较,差异无统计学意义(P>0.05)。治疗后观察组LVEF、LVESV、LVEDV分别为(39.67±4.54)%、(81.48±17.57)ml、(159.52±19.47)ml,均优于对照组的(36.86±4.15)%、(100.05±19.78)ml、(178.48±18.65)ml,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀治疗冠心病疗效显著,可有效的改善患者的心功能以及血脂水平,降低血液流变学水平,值得临床推广应用。
Objective To investigate the effect of statins lipid-lowering drugs on the changes of hemorheology in patients with coronary heart disease. Methods Sixty patients with coronary heart disease were randomly divided into observation group and control group, 30 cases in each. The control group was treated with atorvastatin calcium, and the observation group was given rosuvastatin. The blood rheology and cardiac function of the two groups were compared before and after treatment. Results Before treatment, fibrinogen, plasma viscosity, whole blood low shear viscosity and whole blood high shear viscosity index had no statistical significance (P> 0.05). After treatment, the above indexes in the observation group were lower than those in the control group , The difference was statistically significant (P <0.05). Before treatment, the left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) in the observation group had no significant difference (P> 0.05). The values of LVEF, LVESV and LVEDV in the observation group after treatment were (39.67 ± 4.54)%, (81.48 ± 17.57) ml and (159.52 ± 19.47) ml, respectively, which were all higher than those in the control group (36.86 ± 4.15)% and (100.05 ± 19.78) ml, (178.48 ± 18.65) ml, the difference was statistically significant (P <0.05). Conclusion Rosuvastatin treatment of coronary heart disease significant effect, which can effectively improve the patient’s cardiac function and blood lipid levels, reduce blood rheology, worthy of clinical application.